Last reviewed · How we verify
Pemetrexed and Gemcitabine plus Bevacizumab
Pemetrexed and Gemcitabine plus Bevacizumab is a Small molecule drug developed by Accelerated Community Oncology Research Network. It is currently in Phase 2 development. Also known as: Pemetrexed/Alimta, Gemcitabine/Gemzar, Bevacizumab/Avastin.
At a glance
| Generic name | Pemetrexed and Gemcitabine plus Bevacizumab |
|---|---|
| Also known as | Pemetrexed/Alimta, Gemcitabine/Gemzar, Bevacizumab/Avastin |
| Sponsor | Accelerated Community Oncology Research Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease (PHASE2)
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (PHASE3)
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (PHASE1, PHASE2)
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (PHASE2)
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemetrexed and Gemcitabine plus Bevacizumab CI brief — competitive landscape report
- Pemetrexed and Gemcitabine plus Bevacizumab updates RSS · CI watch RSS
- Accelerated Community Oncology Research Network portfolio CI
Frequently asked questions about Pemetrexed and Gemcitabine plus Bevacizumab
What is Pemetrexed and Gemcitabine plus Bevacizumab?
Pemetrexed and Gemcitabine plus Bevacizumab is a Small molecule drug developed by Accelerated Community Oncology Research Network.
Who makes Pemetrexed and Gemcitabine plus Bevacizumab?
Pemetrexed and Gemcitabine plus Bevacizumab is developed by Accelerated Community Oncology Research Network (see full Accelerated Community Oncology Research Network pipeline at /company/accelerated-community-oncology-research-network).
Is Pemetrexed and Gemcitabine plus Bevacizumab also known as anything else?
Pemetrexed and Gemcitabine plus Bevacizumab is also known as Pemetrexed/Alimta, Gemcitabine/Gemzar, Bevacizumab/Avastin.
What development phase is Pemetrexed and Gemcitabine plus Bevacizumab in?
Pemetrexed and Gemcitabine plus Bevacizumab is in Phase 2.
Related
- Manufacturer: Accelerated Community Oncology Research Network — full pipeline
- Also known as: Pemetrexed/Alimta, Gemcitabine/Gemzar, Bevacizumab/Avastin
- Compare: Pemetrexed and Gemcitabine plus Bevacizumab vs similar drugs
- Pricing: Pemetrexed and Gemcitabine plus Bevacizumab cost, discount & access